Dr. David M. King, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Colorado School of Medicine, Denver (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 430
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: University of Colorado School of Medicine, Denver
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MN license 45762
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Abbott Northwestern Hospital Minneapolis, MN
- Mercy Hospital Coon Rapids, MN
- Cambridge Medical Center Cambridge, MN
Medical groups
- Minnesota Oncology Hematology PA (134 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 430
- Services billed
- 167,175
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 28,050 | 32 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 16,200 | 18 |
| Injection, pembrolizumab, 1 mg | 13,800 | 18 |
| Injection, nivolumab, 1 mg | 12,260 | 16 |
| Injection, denosumab, 1 mg | 6,360 | 17 |
| Injection, aprepitant, 1 mg | 4,160 | 14 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,812 | 49 |
| Injection, granisetron hydrochloride, 100 mcg | 1,660 | 40 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,198 | 258 |
| Blood test, comprehensive group of blood chemicals | 1,022 | 270 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Fridley, MN | 195 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Fridley, MN | 158 |
| Oxycodone Hcl Other prescribers in Fridley, MN | 157 |
| Letrozole Other prescribers in Fridley, MN | 151 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Fridley, MN | 150 |
| Lorazepam Other prescribers in Fridley, MN | 141 |
| Gabapentin Other prescribers in Fridley, MN | 116 |
| Abiraterone Acetate | 115 |
| Omeprazole Other prescribers in Fridley, MN | 105 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Fridley, MN | 98 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $58,511 in research payments for these studies, mostly to the institutions running them.
- Connect MM: The Multiple Myeloma Disease Registry. The purpose of the Connect MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) …
E.r. Squibb & Sons, L.l.c. - Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics, Inc. · Active, not recruiting · NCT03785249 - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatm…
Celgene Corporation - Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Mirati Therapeutics, Inc. · Active, not recruiting · NCT04793958
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.